# Program at a Glance

### Friday, 13 May, 2016

**Opening Remarks**

**Asian Session** Advances in Immunotherapy for Hematological Malignancies

<table>
<thead>
<tr>
<th>Asian Session 1</th>
<th>Asian Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Yu-Hsiang Chang (Taiwan)</td>
<td>Dr. Suporn Chunchanree (Thailand)</td>
</tr>
<tr>
<td>Dr. Xiangyu Zhao (China)</td>
<td>Dr. Hee-Je Kim (Korea)</td>
</tr>
<tr>
<td>Dr. Fumiaki Jinnouchi (Japan)</td>
<td>Dr. Eiko Hayase (Japan)</td>
</tr>
<tr>
<td>Dr. Toshiki Ochi (Japan)</td>
<td>Dr. Yutaka Shimazu (Japan)</td>
</tr>
</tbody>
</table>

**JSH-EHA Joint Session**

Induction of Potent Antitumor T-cell Responses

- **BITE (Bi-specific T-cell Engagers) for ALL**
  - Dr. Nicola Gökbüget (Germany)
- **WT1 Vaccine in MDS/AML**
  - Dr. Naoki Hosen (Japan)
- **Tax Peptide-pulsed Dendritic Cell Vaccine for ATL**
  - Dr. Youko Suehiro (Japan)
- **PD-L1 Specific T Cells**
  - Dr. Mads Hald Andersen (Denmark)

**Luncheon Seminar**

- **Immunotherapy for Multiple Myeloma**
  - Dr. Edward A. Stadtmauer (USA)

**Poster Viewing**

**Plenary Session 1**

Immunotherapy for Lymphoma (Augmentation of Antitumor Immunity by mAbs)

- **The Role of Regulatory T Cells in Treatment of Hematologic Malignancies**
  - Dr. Hiroyoshi Nishikawa (Japan)
- **PD-1 Blockade for the Treatment of Lymphoid Malignancies: Its Usefulness and Challenges**
  - Dr. Momoko Nishikori (Japan)
- **Checkpoint Blockade in Hematologic Malignancy**
  - Dr. Alexander M. Lesokhin (USA)

**JSH/ASH Joint Session**

Genetically Engineered T cells

- **Chimeric Antigen Receptor (CAR) T cells Therapy for Cancer**
  - Dr. Renier J. Brentjens (USA)
- **Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas**
  - Dr. Stephen J. Schuster (USA)
- **Phase I/II Trial of CD19 Chimeric Antigen Receptor T-cell Therapy in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma**
  - Dr. Ken Ohmine (Japan)
- **Adaptive Immunotherapy Using WT1-specific T-cell Receptor Gene-modified Lymphocytes for the Treatment of Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome**
  - Dr. Hiroshi Fujiwara (Japan)

**Break**

### Saturday, 14 May, 2016

**Plenary Session 2**

Posttransplant Immunotherapy

- **The MEK Inhibitor Trametinib Selectively Suppresses GVHD, While Sparing GVT and Antiviral**
  - Dr. Takero Shindo (Japan)
- **Rethinking Regulatory T-cell Homeostasis after HSCT: What’s Going On and How We Modify It.**
  - Dr. Ken-ichi Matsuoka (Japan)
- **Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-cell Transplantation - Updated Results**
  - Dr. Stefan O. Ciurea (USA)

**Special Lecture 1**

- **Microbiome Derived Metabolite Mediated Regulation of GVHD**
  - Dr. Pavan Reddy (USA)

**Special Lecture 2**

- **Hypomethylating Agents in Patients with Myeloid Malignancies Following Allogeneic Blood Stem Cell Transplantation**
  - Dr. Thomas Schroeder (Germany)

**Closing Remarks**

**JSH/ASH Joint Session**

Genetically Engineered T cells

- **Chimeric Antigen Receptor (CAR) T cells Therapy for Cancer**
  - Dr. Renier J. Brentjens (USA)
- **Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas**
  - Dr. Stephen J. Schuster (USA)
- **Phase I/II Trial of CD19 Chimeric Antigen Receptor T-cell Therapy in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma**
  - Dr. Ken Ohmine (Japan)
- **Adaptive Immunotherapy Using WT1-specific T-cell Receptor Gene-modified Lymphocytes for the Treatment of Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome**
  - Dr. Hiroshi Fujiwara (Japan)

**Break**

**Reception**